An Observational Post-authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of rivaroxaban (XARELTO®) initiated in secondary care for the prevention of atherothrombotic events in patients who have had acute coronary syndrome in England and Wales (ROSE ACS)

First published 31/07/2015

Last updated 23/04/2024

EU PAS number:

EUPAS9977

Study

Finalised

Documents

Study protocol

Initial protocol

ACS SCEM Final_30_08_2017_version 7_Clean

English (846.95 KB - PDF)View document

Study results

17542_EU PAS Abstract_Redacted_V1.0_2019-11-21

English (296.37 KB - PDF)View document

DSRU SCEM ACS - Abstract Final Report

English (125.94 KB - PDF)View document

Study report

17542_Clinical Study Report_Redacted_V1.0_2019-11-21

English (8.37 MB - PDF)View document

DSRU EUPAS9977 - Summary Interim Report_3Feb2019

English (86.12 KB - PDF)View document

Other information

Study, other information

DSRU EUPAS9977 - Summary Interim Report_3Feb2019.pdf

English (86.12 KB - PDF)View document

ENCePP Seal

ENCePP Seal documents

Secondary tabs